Biotricity Achieves $14M Revenue Run Rate In August 2023
Portfolio Pulse from Happy Mohamed
Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, reported a record $14 million annualized revenue run rate in August 2023, an increase of over eight percent from the previously announced $13 million run rate. The company's sales growth has been accelerated by better patient outcomes and substantial cost savings, as highlighted in its Corporate Impact Report. The company's Bioflux® cardiac monitoring device identified cardiac events in 4,960 of its 111,552 patients in 2022, leading to early intervention and significant cost savings.
August 30, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biotricity's record $14 million annualized revenue run rate, up from $13 million, indicates strong sales growth. The company's Bioflux® cardiac monitoring device has been instrumental in improving patient outcomes and saving costs, which could further drive revenue growth.
Biotricity's increased revenue run rate indicates strong sales growth, which is likely to positively impact its stock price in the short term. The company's Bioflux® cardiac monitoring device has been successful in improving patient outcomes and saving costs, which could further drive revenue growth and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100